TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Gastric CancerAdenocarcinoma of Esophagogastric Junction
Interventions
DRUG

TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine

"Initial treatment (6 cycles):~1. TQB2450:1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ,from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment:~1)TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2)Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle"

Trial Locations (1)

450008

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV